

# Brian M Wolpin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2612367/publications.pdf>

Version: 2024-02-01

87  
papers

7,936  
citations

76294

40  
h-index

64755

79  
g-index

87  
all docs

87  
docs citations

87  
times ranked

13017  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. <i>Nature</i> , 2017, 547, 453-457.	13.7	1,194
2	Acquired Resistance to KRAS <sup>G12C</sup> Inhibition in Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2382-2393.	13.9	482
3	Systemic Treatment of Colorectal Cancer. <i>Gastroenterology</i> , 2008, 134, 1296-1310.e1.	0.6	418
4	ABO Blood Group and the Risk of Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 424-431.	3.0	321
5	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	15.2	297
6	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , 2014, 46, 994-1000.	9.4	294
7	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2014, 19, 637-638.	1.9	292
8	Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 193-198.	0.8	275
9	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. <i>Cancer Discovery</i> , 2018, 8, 1096-1111.	7.7	256
10	Adjuvant Treatment of Colorectal Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 168-185.	157.7	227
11	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , 2015, 47, 911-916.	9.4	224
12	Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 176-185.	0.8	208
13	Pancreatic Cancer Risk and ABO Blood Group Alleles: Results from the Pancreatic Cancer Cohort Consortium. <i>Cancer Research</i> , 2010, 70, 1015-1023.	0.4	203
14	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. <i>Cell</i> , 2021, 184, 6119-6137.e26.	13.5	201
15	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.	5.8	188
16	Hyperglycemia, Insulin Resistance, Impaired Pancreatic Î²-Cell Function, and Risk of Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1027-1035.	3.0	146
17	Low glycaemic diets alter lipid metabolism to influence tumour growth. <i>Nature</i> , 2021, 599, 302-307.	13.7	142
18	The Mediterranean diet, plasma metabolome, and cardiovascular disease risk. <i>European Heart Journal</i> , 2020, 41, 2645-2656.	1.0	138

#	ARTICLE	IF	CITATIONS
19	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. <i>Cancer Discovery</i> , 2020, 10, 104-123.	7.7	131
20	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , 2020, 38, 800-811.	1.2	106
21	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. <i>American Journal of Human Genetics</i> , 2015, 96, 487-497.	2.6	101
22	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. <i>Cancer Cell</i> , 2020, 38, 198-211.e8.	7.7	99
23	Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. <i>Nature Communications</i> , 2020, 11, 4296.	5.8	98
24	Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data. <i>PLoS Genetics</i> , 2016, 12, e1006493.	1.5	98
25	Plasma 25-Hydroxyvitamin D and Risk of Pancreatic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 82-91.	1.1	97
26	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014, 23, 6616-6633.	1.4	90
27	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. <i>Oncotarget</i> , 2016, 7, 66328-66343.	0.8	88
28	Discovery of a selective inhibitor of doublecortin like kinase 1. <i>Nature Chemical Biology</i> , 2020, 16, 635-643.	3.9	84
29	Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4574-4586.	3.2	82
30	Population-Scale CT-based Body Composition Analysis of a Large Outpatient Population Using Deep Learning to Derive Age-, Sex-, and Race-specific Reference Curves. <i>Radiology</i> , 2021, 298, 319-329.	3.6	80
31	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. <i>Cancer Discovery</i> , 2021, 11, 2014-2031.	7.7	79
32	Variant ABO Blood Group Alleles, Secretor Status, and Risk of Pancreatic Cancer: Results from the Pancreatic Cancer Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3140-3149.	1.1	78
33	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. <i>Cell</i> , 2020, 181, 832-847.e18.	13.5	77
34	Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. <i>Gastroenterology</i> , 2021, 160, 1373-1383.e6.	0.6	77
35	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. <i>Nature Communications</i> , 2020, 11, 3353.	5.8	75
36	Circulating Insulin-Like Growth Factor Binding Protein-1 and the Risk of Pancreatic Cancer. <i>Cancer Research</i> , 2007, 67, 7923-7928.	0.4	71

#	ARTICLE	IF	CITATIONS
37	Critical role for arginase 2 in obesity-associated pancreatic cancer. <i>Nature Communications</i> , 2017, 8, 242.	5.8	67
38	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1003-1012.	3.0	59
39	<sc><i>TERT</i></sc> gene harbors multiple variants associated with pancreatic cancer susceptibility. <i>International Journal of Cancer</i> , 2015, 137, 2175-2183.	2.3	57
40	Quantifying the Genetic Correlation between Multiple Cancer Types. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1427-1435.	1.1	48
41	Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. <i>Cancer Research</i> , 2016, 76, 7160-7167.	0.4	46
42	Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. <i>Oncologist</i> , 2013, 18, 377-378.	1.9	40
43	Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. <i>Nature Communications</i> , 2017, 8, 15034.	5.8	40
44	Leucocyte telomere length, genetic variants at the <i>TERT</i> gene region and risk of pancreatic cancer. <i>Gut</i> , 2017, 66, 1116-1122.	6.1	39
45	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1185-1191.	1.1	29
46	Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. <i>Cell Reports</i> , 2020, 33, 108493.	2.9	28
47	Covariate selection for association screening in multiphenotype genetic studies. <i>Nature Genetics</i> , 2017, 49, 1789-1795.	9.4	27
48	Characterising <i>cis</i>-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. <i>Gut</i> , 2018, 67, 521-533.	6.1	26
49	Functional characterization of a chr13q22.1 pancreatic cancer risk locus reveals long-range interaction and allele-specific effects on <i>DIS3</i> expression. <i>Human Molecular Genetics</i> , 2016, 25, ddw300.	1.4	24
50	Phase I Study of Gefitinib plus FOLFIRI in Previously Untreated Patients with Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2006, 6, 208-213.	1.0	21
51	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 557-567.	3.0	21
52	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). <i>Journal of the National Cancer Institute</i> , 2019, 111, 170-179.	3.0	19
53	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 999-1008.	1.1	19
54	Circulating Exosomes in Pancreatic Cancer: Will They Succeed on the Long, Littered Road to Early Detection Marker?. <i>Clinical Chemistry</i> , 2016, 62, 307-309.	1.5	17

#	ARTICLE	IF	CITATIONS
55	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. <i>Genome Medicine</i> , 2021, 13, 15.	3.6	15
56	A 584Åbp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. <i>American Journal of Human Genetics</i> , 2021, 108, 1852-1865.	2.6	15
57	Variants Associated with Susceptibility to Pancreatic Cancer and Melanoma Do Not Reciprocally Affect Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1121-1124.	1.1	14
58	Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. <i>JCO Precision Oncology</i> , 2021, 5, 1325-1338.	1.5	14
59	A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. <i>Investigational New Drugs</i> , 2020, 38, 1533-1539.	1.2	13
60	Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 761-776.	0.9	11
61	Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2022, 8, 88.	3.4	11
62	Pancreatic Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, xiii-xiv.	0.9	10
63	Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early Detection. <i>Frontiers in Oncology</i> , 2020, 10, 596931.	1.3	10
64	When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 485-489.	0.8	9
65	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 1408-1417.	2.2	9
66	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. <i>Cancer Research</i> , 2021, 81, 3134-3143.	0.4	8
67	Managing Advanced Colorectal Cancer: Have We Reached the PEAK With Current Therapies?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2200-2202.	0.8	6
68	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2735-2739.	1.1	6
69	The Writing on the Wall. <i>New England Journal of Medicine</i> , 2009, 361, 1387-1392.	13.9	5
70	Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1784-1791.	1.1	5
71	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. <i>Cancer Research</i> , 2020, 80, 4004-4013.	0.4	5
72	Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3199-3206.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Surveillance Imaging in Individuals at High Risk for Pancreatic Cancer: Not a Ceiling, but Rather a Floor Upon Which to Build. <i>Gastroenterology</i> , 2022, 162, 700-702.	0.6	5
74	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. <i>Practical Radiation Oncology</i> , 2014, 4, e117-e123.	1.1	4
75	Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. <i>American Journal of Roentgenology</i> , 2019, 212, 596-601.	1.0	4
76	A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 296-296.	0.8	2
77	A phase 1b study evaluating IL-1 $\hat{I}$ 2 and PD-1 targeting with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).. <i>Journal of Clinical Oncology</i> , 2022, 40, 557-557.	0.8	2
78	Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study. <i>BMJ Open Sport and Exercise Medicine</i> , 2022, 8, e001353.	1.4	2
79	Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10528-10528.	0.8	1
80	G-CSF-induced carotid inflammation. <i>Lancet Oncology</i> , The, 2022, 23, e235.	5.1	1
81	Reply to Y. Mao et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 2121-2122.	0.8	0
82	Reply to A. Braillon. <i>Journal of Clinical Oncology</i> , 2017, 35, 1136-1137.	0.8	0
83	Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial. , 2021, , .		0
84	Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 301-301.	0.8	0
85	Feasibility of computer-based self-administered cancer-specific geriatric assessment (SA-CSGA) in older pts with gastrointestinal malignancy (GIM).. <i>Journal of Clinical Oncology</i> , 2012, 30, e19586-e19586.	0.8	0
86	Identification of the Metabolomic Fingerprint Associated with Flavonoid Consumption Level. <i>FASEB Journal</i> , 2015, 29, 745.7.	0.2	0
87	Initial efficacy and biomarker analysis of a phase 1b study targeting IL-1 $\hat{I}$ 2 and PD-1 with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16287-e16287.	0.8	0